請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/24495
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 顧記華 | |
dc.contributor.author | Ya-Ling Chan | en |
dc.contributor.author | 詹雅玲 | zh_TW |
dc.date.accessioned | 2021-06-08T05:28:16Z | - |
dc.date.copyright | 2005-08-04 | |
dc.date.issued | 2005 | |
dc.date.submitted | 2005-07-12 | |
dc.identifier.citation | Reference List
1. Jordan, M. A. & Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4, 253-265 (2004). 2. Kaina, B. DNA damage-triggered apoptosis: critical role of DNA repair, double-strand breaks, cell proliferation and signaling. Biochem. Pharmacol. 66, 1547-1554 (2003). 3. Meresse, P., Dechaux, E., Monneret, C. & Bertounesque, E. Etoposide: discovery and medicinal chemistry. Curr. Med. Chem. 11, 2443-2466 (2004). 4. Kalyanaraman, B. Joseph,J. Kalivendi,S. Wang,S. Konorev,E. Kotamraju,S. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol. Cell Biochem. 234-235, 119-124 (2002). 5. Nielsen, D., Maare, C. & Skovsgaard, T. Cellular resistance to anthracyclines. Gen. Pharmacol. 27, 251-255 (1996). 6. Perry, P. J. Gowan,S.M. Reszka,A.P. Polucci,P. Jenkins,T.C. Kelland,L.R. Neidle,S. 1,4- and 2,6-disubstituted amidoanthracene-9,10-dione derivatives as inhibitors of human telomerase. J. Med. Chem. 41, 3253-3260 (1998). 7. Kerr, J. F., Wyllie, A. H. & Currie, A. R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26, 239-257 (1972). 8. Kass, G. E., Eriksson, J. E., Weis, M., Orrenius, S. & Chow, S. C. Chromatin condensation during apoptosis requires ATP. Biochem. J. 318 ( Pt 3), 749-752 (1996). 9. Levee, M. G., Dabrowska, M. I., Lelli, J. L., Jr. & Hinshaw, D. B. Actin polymerization and depolymerization during apoptosis in HL-60 cells. Am. J. Physiol 271, C1981-C1992 (1996). 10. Fadok, V. A. Voelker,D.R. Campbell,P.A. Cohen,J.J. Bratton,D.L. Henson,P.M. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 148, 2207-2216 (1992). 11. Okada, H. & Mak, T. W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. Cancer 4, 592-603 (2004). 12. Cory, S., Huang, D. C. & Adams, J. M. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22, 8590-8607 (2003). 13. Gross, A., McDonnell, J. M. & Korsmeyer, S. J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13, 1899-1911 (1999). 14. Nguyen, M., Millar, D. G., Yong, V. W., Korsmeyer, S. J. & Shore, G. C. Targeting of Bcl-2 to the mitochondrial outer membrane by a COOH-terminal signal anchor sequence. J. Biol. Chem. 268, 25265-25268 (1993). 15. Cheng, E. H. Wei,M.C. Weiler,S. Flavell,R.A. Mak,T.W. Lindsten,T. Korsmeyer,S.J. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell 8, 705-711 (2001). 16. Shiozaki, E. N. & Shi, Y. Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology. Trends Biochem. Sci. 29, 486-494 (2004). 17. Salvesen, G. S. & Duckett, C. S. IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell Biol. 3, 401-410 (2002). 18. Saelens, X. Festjens,N. Vande,Walle L. van,Gurp M. van,Loo G. Vandenabeele,P. Toxic proteins released from mitochondria in cell death. Oncogene 23, 2861-2874 (2004). 19. Susin, S. A. Lorenzo,H.K. Zamzami,N. Marzo,I. Snow,B.E. Brothers,G.M. Mangion,J. Jacotot,E. Costantini,P. Loeffler,M. Larochette,N. Goodlett,D.R. Aebersold,R. Siderovski,D.P. Penninger,J.M. Kroemer,G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397, 441-446 (1999). 20. Li, L. Y., Luo, X. & Wang, X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 412, 95-99 (2001). 21. Arnoult, D. Gaume,B. Karbowski,M. Sharpe,J.C. Cecconi,F. Youle,R.J. Mitochondrial release of AIF and EndoG requires caspase activation downstream of Bax/Bak-mediated permeabilization. EMBO J. 22, 4385-4399 (2003). 22. Valentijn, A. J. & Gilmore, A. P. Translocation of full-length Bid to mitochondria during anoikis. J. Biol. Chem. 279, 32848-32857 (2004). 23. Wang, L., Miura, M., Bergeron, L., Zhu, H. & Yuan, J. Ich-1, an Ice/ced-3-related gene, encodes both positive and negative regulators of programmed cell death. Cell 78, 739-750 (1994). 24. Lassus, P., Opitz-Araya, X. & Lazebnik, Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science 297, 1352-1354 (2002). 25. Robertson, J. D. Gogvadze,V. Kropotov,A. Vakifahmetoglu,H. Zhivotovsky,B. Processed caspase-2 can induce mitochondria-mediated apoptosis independently of its enzymatic activity. EMBO Rep. 5, 643-648 (2004). 26. Rutkowski, D. T. & Kaufman, R. J. A trip to the ER: coping with stress. Trends Cell Biol. 14, 20-28 (2004). 27. Harding, H. P., Calfon, M., Urano, F., Novoa, I. & Ron, D. Transcriptional and translational control in the Mammalian unfolded protein response. Annu. Rev. Cell Dev. Biol. 18, 575-599 (2002). 28. Wang, X. Z. Miura,M. Bergeron,L. Zhu,H. Yuan,J. Signals from the stressed endoplasmic reticulum induce C/EBP-homologous protein (CHOP/GADD153). Mol. Cell Biol. 16, 4273-4280 (1996). 29. Tombal, B., Weeraratna, A. T., Denmeade, S. R. & Isaacs, J. T. Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells. Prostate 43, 303-317 (2000). 30. McCullough, K. D., Martindale, J. L., Klotz, L. O., Aw, T. Y. & Holbrook, N. J. Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state. Mol. Cell Biol. 21, 1249-1259 (2001). 31. Urano, F. Wang,X. Bertolotti,A. Zhang,Y. Chung,P. Harding,H.P. Ron,D. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 287, 664-666 (2000). 32. Takeda, K., Matsuzawa, A., Nishitoh, H. & Ichijo, H. Roles of MAPKKK ASK1 in stress-induced cell death. Cell Struct. Funct. 28, 23-29 (2003). 33. Lamkanfi, M., Kalai, M. & Vandenabeele, P. Caspase-12: an overview. Cell Death. Differ. 11, 365-368 (2004). 34. Catalona, W. J. Partin,A.W. Slawin,K.M. Naughton,C.K. Brawer,M.K. Flanigan,R.C. Richie,J.P. Patel,A. Walsh,P.C. Scardino,P.T. Lange,P.H. deKernion,J.B. Southwick,P.C. Loveland,K.G. Parson,R.E. Gasior,G.H. Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial. Urology 55, 372-376 (2000). 35. Sim, H. G. & Cheng, C. W. Changing demography of prostate cancer in Asia. Eur. J. Cancer 41, 834-845 (2005). 36. Pu, Y. S. Chiang,H.S. Lin,C.C. Huang,C.Y. Huang,K.H. Chen,J. Changing trends of prostate cancer in Asia. Aging Male. 7, 120-132 (2004). 37. Micheau, O., Solary, E., Hammann, A. & manche-Boitrel, M. T. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J. Biol. Chem. 274, 7987-7992 (1999). 38. Scheel-Toellner, D. Wang,K. Assi,L.K. Webb,P.R. Craddock,R.M. Salmon,M. Lord,J.M. Clustering of death receptors in lipid rafts initiates neutrophil spontaneous apoptosis. Biochem. Soc. Trans. 32, 679-681 (2004). 39. Johnson, G. L. & Lapadat, R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298, 1911-1912 (2002). 40. Chen, K. Kuo,S.C. Hsieh,M.C. Mauger,A. Lin,C.M. Hamel,E. Lee,K.H. Antitumor agents. 174. 2',3',4',5,6,7-Substituted 2-phenyl-1,8-naphthyridin-4-ones: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. J. Med. Chem. 40, 2266-2275 (1997). 41. Stewart, Z. A., Westfall, M. D. & Pietenpol, J. A. Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol. Sci. 24, 139-145 (2003). 42. Bhalla, K. N. Microtubule-targeted anticancer agents and apoptosis. Oncogene 22, 9075-9086 (2003). 43. Skoufias, D. A. & Wilson, L. Mechanism of inhibition of microtubule polymerization by colchicine: inhibitory potencies of unliganded colchicine and tubulin-colchicine complexes. Biochemistry 31, 738-746 (1992). 44. Ito, T., Deng, X., Carr, B. & May, W. S. Bcl-2 phosphorylation required for anti-apoptosis function. J. Biol. Chem. 272, 11671-11673 (1997). 45. Haldar, S., Chintapalli, J. & Croce, C. M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 56, 1253-1255 (1996). 46. Basu, A. & Haldar, S. Identification of a novel Bcl-xL phosphorylation site regulating the sensitivity of taxol- or 2-methoxyestradiol-induced apoptosis. FEBS Lett. 538, 41-47 (2003). 47. Herrant, M. Jacquel,A. Marchetti,S. Belhacene,N. Colosetti,P. Luciano,F. Auberger,P. Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene 23, 7863-7873 (2004). 48. Dirsch, V. M., Kirschke, S. O., Estermeier, M., Steffan, B. & Vollmar, A. M. Apoptosis signaling triggered by the marine alkaloid ascididemin is routed via caspase-2 and JNK to mitochondria. Oncogene 23, 1586-1593 (2004). 49. Ott, M., Robertson, J. D., Gogvadze, V., Zhivotovsky, B. & Orrenius, S. Cytochrome c release from mitochondria proceeds by a two-step process. Proc. Natl. Acad. Sci. U. S. A 99, 1259-1263 (2002). 50. Otera, H., Ohsakaya, S., Nagaura, Z., Ishihara, N. & Mihara, K. Export of mitochondrial AIF in response to proapoptotic stimuli depends on processing at the intermembrane space. EMBO J. 24, 1375-1386 (2005). 51. Polster, B. M., Basanez, G., Etxebarria, A., Hardwick, J. M. & Nicholls, D. G. Calpain I induces cleavage and release of apoptosis-inducing factor from isolated mitochondria. J. Biol. Chem. 280, 6447-6454 (2005). 52. Zhu, D. M. & Uckun, F. M. Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells. Clin. Cancer Res. 6, 2456-2463 (2000). 53. Skladanowski, A. & Konopa, J. Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells. Br. J. Cancer 82, 1300-1304 (2000). 54. de,Isabella P. Palumbo,M. Sissi,C. Carenini,N. Capranico,G. Menta,E. Oliva,A.; Spinelli,S. Krapcho,A.P. Giuliani,F.C. Zunino,F. Physicochemical properties, cytotoxic activity and topoisomerase II inhibition of 2,3-diaza-anthracenediones. Biochem. Pharmacol. 53, 161-169 (1997). 55. Sadeghi-Aliabadi, H., Tabarzadi, M. & Zarghi, A. Synthesis and cytotoxic evaluation of two novel anthraquinone derivatives. Farmaco 59, 645-649 (2004). 56. Gatto, B. Zagotto,G. Sissi,C. Cera,C. Uriarte,E. Palu,G. Capranico,G. Palumbo,M.Peptidyl anthraquinones as potential antineoplastic drugs: synthesis, DNA binding, redox cycling, and biological activity. J. Med. Chem. 39, 3114-3122 (1996). 57. Bailly, C., Routier, S., Bernier, J. L. & Waring, M. J. DNA recognition by two mitoxantrone analogues: influence of the hydroxyl groups. FEBS Lett. 379, 269-272 (1996). 58. Kapuscinski, J. & Darzynkiewicz, Z. Relationship between the pharmacological activity of antitumor drugs Ametantrone and mitoxantrone (Novatrone) and their ability to condense nucleic acids. Proc. Natl. Acad. Sci. U. S. A 83, 6302-6306 (1986). 59. Routier, S., Bernier, J. L., Catteau, J. P., Riou, J. F. & Bailly, C. Synthesis, DNA binding, topoisomerase II inhibition and cytotoxicity of two guanidine-containing anthracene-9,10-diones. Anticancer Drug Des 13, 407-415 (1998). 60. Covacci, V. Bruzzese,N. Sgambato,A. Ganapathi,R. Cittadini,A. Wolf,F.I. Effect of extracellular magnesium on topoisomerase II activity and expression in human leukemia HL-60 cells. J. Cell Biochem. 78, 325-333 (2000). 61. Feofanov, A. Charonov,S. Fleury,F. Kudelina,I. Jardillier,J.C. Nabiev,I. Confocal spectral imaging analysis of intracellular interactions of mitoxantrone at different phases of the cell cycle. Anticancer Res. 19, 5341-5348 (1999). 62. Smith, P. J., Blunt, N. J., Desnoyers, R., Giles, Y. & Patterson, L. H. DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides. Cancer Chemother. Pharmacol. 39, 455-461 (1997). 63. Augustin, E., Wheatley, D. N., Lamb, J. & Konopa, J. Imidazoacridinones arrest cell-cycle progression in the G2 phase of L1210 cells. Cancer Chemother. Pharmacol. 38, 39-44 (1996). 64. Downes, C. S. A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells. Nature 372, 467-470 (1994). 65. Van de, C. M., Declercq, W., Van, d. b., I, Fiers, W. & Vandenabeele, P. The proteolytic procaspase activation network: an in vitro analysis. Cell Death. Differ. 6, 1117-1124 (1999). 66. Robertson, J. D., Enoksson, M., Suomela, M., Zhivotovsky, B. & Orrenius, S. Caspase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis. J. Biol. Chem. 277, 29803-29809 (2002). 67. Zhivotovsky, B. & Orrenius, S. Caspase-2 function in response to DNA damage. Biochem. Biophys. Res. Commun. 331, 859-867 (2005). 68. Norbury, C. J. & Zhivotovsky, B. DNA damage-induced apoptosis. Oncogene 23, 2797-2808 (2004). 69. Kharbanda, S., Yuan, Z. M., Weichselbaum, R. & Kufe, D. Determination of cell fate by c-Abl activation in the response to DNA damage. Oncogene 17, 3309-3318 (1998). 70. Tournier, C. Hess,P. Yang,D.D. Xu,J. Turner,T.K. Nimnual,A. Bar-Sagi,D. Jones,S.N. Flavell,R.A. Davis,R.J. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 288, 870-874 (2000). 71. Park, M. T. Choi,J.A. Kim,M.J. Um,H.D. Bae,S.; Kang,C.M. Cho,C.K. Kang,S. Chung,H.Y. Lee,Y.S. Lee,S.J. Suppression of extracellular signal-related kinase and activation of p38 MAPK are two critical events leading to caspase-8- and mitochondria-mediated cell death in phytosphingosine-treated human cancer cells. J. Biol. Chem. 278, 50624-50634 (2003). 72. Stadheim, T. A. & Kucera, G. L. c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for mitoxantrone- and anisomycin-induced apoptosis in HL-60 cells. Leuk. Res. 26, 55-65 (2002). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/24495 | - |
dc.description.abstract | 在歐美等西方國家,前列腺癌為男性好發的癌症之一,在美國每年約有三萬人死於前列腺癌;在台灣,前列腺癌也晉升為十大癌症死亡因素。但是就目前為止,對於前列腺癌的治療尚未有一個有效的藥物,有鑑於此,發展一個有效對抗前列腺癌的抗癌藥物,對於癌症的治療是必須的。於是在本篇論文的第一部分中,我們使用sulforhodamine B (SRB)的分析方法,以男性素不依賴型的前列腺癌細胞株PC-3為細胞模式,針對多種化合物進行抗癌活性篩選。我們發現化合物LYF-5(3’-methoxyl- 2-phenyl-6-methyl-1,8-naphthyridine-4-one)能有效的抑制癌細胞的生長,其達到50%的抑制濃度(IC50)為0.12 μM。因此,我們便進一步探討其抗癌作用機轉。我們使用TUNEL做螢光染色,證實LYF-5的確會造成細胞的凋亡作用(apoptosis)。我們也以propidium iodide結合到細胞DNA,利用流式細胞儀來分析探討LYF-5對於細胞週期的影響。結果發現在LYF-5的作用下,能促使細胞的週期停止在G2/M期,並在作用24小時之後明顯的引起細胞subG1期(Hypodiploid phase,代表細胞凋亡)的增加。使用共軛焦顯微鏡觀察LYF-5對細胞微小管(microtubule)的作用,發現LYF-5能直接影響微小管的聚合作用。接下來,我們利用西方墨點法來探討Bcl-2家族蛋白、caspases以及其他與細胞凋亡有關的蛋白在LYF-5作用下的表現情形。結果顯示,LYF-5能造成Bcl-2與Bcl-xL的磷酸化,並使得Mcl-l的表現下降;同時也發現在LYF-5作用之下會造成Bcl-2與Mcl-1的斷裂。在caspases方面,caspase-3、caspase-8與caspase-9皆受到明顯的活化;另外LYF-5也會抑制XIAP(X-type inhibitor of apoptosis protein)與cIAP2的表現。 最後,我們使用共軛焦顯微鏡進行免疫螢光染色的實驗,以觀察在LYF-5的作用之下是否會造成粒線體中cytochrome c的釋放作用;由實驗的結果顯示LYF-5的確會造成細胞cytochrome c釋放至細胞質中。綜合以上的結果,我們可以認為LYF-5造成癌細胞進行細胞凋亡作用,首先是藉由直接影響微小管而造成細胞週期停止在G2/M期,之後磷酸化Bcl-2以及Bcl-xL這兩個抑制細胞進行凋亡的蛋白,並造成Mcl-1蛋白的裂解作用,接下來活化一系列的caspases蛋白並促使cytochrome c的釋放,最後導致細胞進行凋亡作用。
而在本論文的第二部份中,主要是針對一系列anthracenedione衍生物在前列腺癌細胞PC-3的抗癌作用,對其結構與作用的相關性以及可能的作用機轉做探討。藉由SRB assay的篩選,我們找到其中抗癌活性最強的化合物為WRC-76,其IC50是0.28 μM。為了了解這一系列化合物的作用機轉,我們以WRC-76為代表,觀察其對於細胞週期的影響。由實驗結果得知WRC-76能造成細胞的週期停止於S期,在長時間作用下能造成細胞的週期停止於G2/M期;並且高濃度的WRC-76會使細胞進行凋亡作用。接下來我們使用螢光染色的方式觀察WRC-76對於細胞微小管的形成是否造成影響,由結果發現WRC-76並不會影響微小管的形成作用。為了更進一步了解WRC-76的作用機轉,我們使用西方墨點法觀察WRC-76對於細胞內蛋白的影響,由實驗結果得知在藥物作用之下,Bcl-2蛋白家族只有Mcl-1的表現受到抑制。另外,WRC-76能藉由活化caspase-8、caspase-9與caspase-3來導致細胞凋亡。Death Receptorreceptor包括DR4、DR5以及Fas,以及他們的Ligandligand包括TRAIL以及FasL在WRC-76作用之下,皆不受到影響。另外我們使用螢光顯微鏡觀察細胞內Fas聚集(clustering)的情形,由實驗結果發現WRC-76並不會造成Fas的聚集作用。XIAP與survivin主要的功能為抑制caspases的活化,在WRC-76的作用之下,XIAP的表現量減少,這與細胞凋亡作用的結果是一致的,但是survivin卻不受影響。Caspase-12、CHOP以及CRP78是內質網受到壓力(Endoplasmic reticulum stress)會被活化的蛋白。在WRC-76作用下可以觀察到casapase-12以及CHOP的活化。並且在WRC-76的作用之下,能夠導致JNK以及p38這兩個MAP kinase的活化。綜合以上結果得知,WRC-76除了藉由活化caspase-8、caspase-9以及caspase-3的路徑導致細胞凋亡外,WRC-76另一方面還會造成內質網壓力,並活化caspase-12造成細胞凋亡。而在WRC-76作用之下可以看到JNK與p38這兩個MAP kinase的活化,而這兩個MAP kinase也同樣使細胞走向凋亡。 | zh_TW |
dc.description.abstract | Prostate cancer is the most frequently diagnosed malignancy in males in the United States and most other industrialized Western countries. It kills more than 30,000 American men yearly and it is one of the top 10 deadliest cancers in Taiwan. There have been no therapeutic agents that provide a survival advantage in prostate cancer. Therefore, it is necessary to develop novel agents for the treatment of hormone-refractory prostate cancer.
In the first part of this study, we used human hormone-resistant prostate cancer cell line PC-3 to investigate the anti-tumor effect and mechanism of compound LYF-5 (3’-methoxyl-2-phenyl-6-methyl-1,8-naphthyridine-4-one). LYF-5 inhibited cell growth in a dose-dependent manner with an IC50 of 0.12 μM by sulforhodamine B (SRB) assays. Using FACScan flow cytometric analysis, the data showed that LYF-5 induced the arrest of cells in G2/M phase of the cell cycle and a subsequent increase of hypodiploid sub-G1 cells. The apoptotic cell death was also identified by TUNEL reaction technique. Immunofluoresence microscopic examination indicated that LYF-5 had an action target on tubulin/microtubule. Several apoptosis-related proteins were examined in this study. After the detection of expression of Bcl-2 family members by Western blotting, the data showed that LYF-5 induced phosphorylation of Bcl-2 and Bcl-xL, and Mcl-1 down-regulation. In addition, the cleaved forms of Mcl-1 was also apparent. Moreover, LYF-5-induced apoptosis was associated with processing of pro-caspase-8, pro-caspase-3 and pro-caspase-9, indicating the involvement of caspase activation. The expression of XIAP and cIAP2 were decreased after treating with LYF-5. Furthermore, we used immunofluoresence microscopic examination to examine the release reaction of cytochrome c. The data showed that LYF-5 significantly induced the release of cytochrome c from mitochondria. Taken together, it is suggested that LYF-5 induces apoptotic cell death through the target on tubulin/microtubule, the induction of mitotic arrest of the cell cycle, phosphorylation and cleavage of anti-apoptotic Bcl-2 family protein members, the activation of caspase and the release of cytochrome c. In the second part of this study, the structure-activity relationship of a series of anthracenedione derivatives on anticancer activity and their action mechanisms in human hormone-resistant prostate cancer PC-3 cells were investigated. By using SRB assays, we found that several compounds displayed anticancer activity and amongst, WRC-76 was the most effective one with an IC50 of 0.28 μM. Accordingly, WRC-76 was selected for the mechanism study. The data showed that WRC-76 induced the arrest of the cell cycle in S and G2/M phase and a subsequent increase of hypodiploid sub-G1 phase. Immunofluoresence microscopic examination indicated that WRC-76 had no effect on tubulin/microtubule function. Several apoptosis-related proteins were examined in this study. After the detection of expression of Bcl-2 family members by Western blotting, the data showed that the expression of Mcl-1 was decreased after theatment with WRC-76. Moreover, WRC-76-induced cell apoptosis was associated with processing of pro-caspase-8, pro-caspase-3 and pro-caspase-9. The expression of XIAP but not survivin was inhibited by WRC-76. Caspase-12, CHOP and GRP78 are three ER stress markers and the expression of caspase-12 and CHOP were significantly increased by WRC76. Furthermore, JNK and p38 MAP kinases involved pathways were also activated in cells responsive to WRC-76. Taken together, it is suggested that WRC-76 induces apoptotic cell death through the activation of caspase-8, -9 and -3. WRC-76 also induces the ER stress of increase of CHOP expression and caspase-12 activity. Furthermore, the activation of JNK and p38 MAPK may, at least partly, explain WRC-76-induced apoptotic cell death. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T05:28:16Z (GMT). No. of bitstreams: 1 ntu-94-R92423018-1.pdf: 2974797 bytes, checksum: bb27f94c1b81d9a7b22a877691180c74 (MD5) Previous issue date: 2005 | en |
dc.description.tableofcontents | 縮寫表……………………………………………………………………I
中文摘要………………………………………………………......III 英文摘要…………………………………………………………...V 壹、前言 抗癌藥物與癌症的治療.................................1 細胞凋亡(apoptosis)與細胞壞死(necrosis)..............3 細胞凋亡相關的訊息傳遞物質Bcl-2 蛋白家族…….........3 與細胞凋亡訊息相關的Caspases、IAPs…………...........4 粒線體內與細胞凋亡相關的蛋白.........................5 細胞凋亡機轉………………………………………….........5 研究動機.............................................7 貳、實驗材料與方法 實驗材料………………………………………...............9 細胞培養………………………………………...............9 實驗方法 細胞計數……………………………………............10 細胞生長的測定(SRB偵測法)………….............…10 TUNEL測定法(In situ labeling of apoptosis cell)…….11 流式細胞儀( flow cytometry )測定細胞凋亡與細胞週…..11 Mitotic spindles之螢光免疫偵測…………..…......…..12 Tubulin聚合實驗.....................................12 Cytochrome c、AIF 釋放作用之螢光免疫偵測........... 12 西方墨點法……………………………………..………………13 資料分析............................................14 參、實驗結果 第一部份 探討LYF-5的作用機轉....................15 第二部份 探討anthracenedione衍生物作用機轉......19 肆、實驗討論 第一部份 探討LYF-5的作用機轉討論................24 第二部份 探討anthracenedione衍生物作用機轉討論..29 伍、結論…………………………………....................37 附....圖..............................................39 參考文獻..............................................76 | |
dc.language.iso | zh-TW | |
dc.title | 探討LYF-5與anthracenedione衍生物在人類荷爾蒙不依賴型前列腺癌細胞的抗癌作用機轉 | zh_TW |
dc.title | Investigation of anticancer mechanism of LYF-5 and anthracenedione analogues in hormone- resistant prostate cancer PC-3 Cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 93-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陳基旺,孔繁璐,忻凌偉,蕭哲志 | |
dc.subject.keyword | 細胞凋亡,前列腺癌,微小管,染色體, | zh_TW |
dc.subject.keyword | apoptosis,prostate cancer,microtubule,DNA, | en |
dc.relation.page | 82 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2005-07-12 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-94-1.pdf 目前未授權公開取用 | 2.91 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。